Skip to content

Psilocybin for anxiety

Studies whose primary subject is both Psilocybin and Anxiety, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, Anxiety, generalized anxiety disorder, then ranked by relevance.

The research generally points toward psilocybin reducing anxiety, especially in people with cancer-related distress and depression, where single or few doses alongside psychological support produced large, often sustained improvements (roughly 60-80% of participants showing clinically significant anxiety reductions at follow-up). Results are fairly consistent across trials and reviews, but the evidence base is small: most clinical studies have 12-51 participants, several are open-label or crossover with limited blinding, and some anxiety gains track improvements in depression rather than standing alone. Larger, well-blinded trials with anxiety as a primary endpoint are still needed.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial 2016 RCT 51 Supports High-dose psilocybin produced large decreases in clinician- and self-rated anxiety and depressed mood, with about 80% still showing clinically significant improvement at 6 months.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial 2016 RCT 29 Supports Single-dose psilocybin plus psychotherapy produced immediate, substantial anxiety and depression improvements, with roughly 60-80% retaining clinically significant reductions at 6.5 months.
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer 2010 double-blind placebo-controlled pilot 12 Supports Psilocybin was safe and associated with significant reductions in trait anxiety at 1 and 3 months and improved mood.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance 2006 double-blind study 36 Mixed Psilocybin produced acute perceptual changes and labile moods including anxiety, alongside increased mystical-type experience ratings.
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression 2018 clinical trial 20 Supports Oceanic boundlessness and dread of ego dissolution during the psilocybin session predicted depressive symptom improvement at 5 weeks.
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder 2006 controlled clinical trial Supports Psilocybin was safely used and associated with acute reductions in core OCD symptoms in several subjects.
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies 2010 pooled analysis 110 Mixed Most subjects found psilocybin pleasurable and enriching, but acute anxiety/panic reactions occurred in a small proportion at the two highest doses and were managed with support alone.
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up 2022 randomized waiting-list controlled 27 Supports Psilocybin-assisted therapy produced large antidepressant effects through 12 months, with 75% response and 58% remission.
Emotions and brain function are altered up to one month after a single high dose of psilocybin. 2020 open-label pilot 12 Supports A single high dose reduced negative affect and amygdala reactivity at one week and lowered trait anxiety at one month.
Psychedelics as Medicines: An Emerging New Paradigm 2016 theoretical Supports Argues that psychedelics may treat anxiety and depression by acutely destabilizing brain network hubs and enabling network resetting.
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms 2016 questionnaire validation Mixed Identified seven factors of challenging psilocybin experiences, including fear, that were associated with difficulty and changes in well-being, with factor structure not differing by prior anxiety or depression.
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies 2020 systematic review 188 Supports Psychedelic-assisted therapy appeared safe with promising early efficacy for depression, anxiety, OCD, and substance use disorders, with effects often lasting weeks to months after 1-3 sessions.
Psychedelics and Mental Health: A Population Study 2013 cross-sectional survey 130152 No effect Lifetime psychedelic use was not associated with increased rates of mental health problems, including general anxiety disorder, and in some cases was associated with lower rates.
Dynamic coupling of whole-brain neuronal and neurotransmitter systems 2020 observational neuroimaging Unclear Describes a framework causally linking 5-HT2A receptor stimulation by psilocybin to brain functional effects, with relevance to depression and anxiety proposed for future work.
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years 2016 systematic review Supports Reviewed trials suggest beneficial effects of ayahuasca, psilocybin, and LSD for anxiety and depression associated with life-threatening illness and treatment-resistant depression, but all had small samples and half were open-label.
Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice. 2026 controlled animal experiment Supports Mice lacking 5-HT1B receptors on forebrain excitatory neurons showed strongly attenuated post-acute anxiolytic effects of psilocybin, implicating these receptors in its anxiety-reducing action.
Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe Anxiety 2026 in vitro experimental Mixed Psilocybe cubensis extract altered gut microbial metabolites and immune responses in a complex, non-uniform pattern in microbiota from anxious individuals.
A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults. 2026 Phase 1 RCT 56 No effect Low psilocybin doses produced dose-related subjective effects without significant perceptual alterations, cognitive impairment, or increased anxiety.
Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder 2026 review Supports Reports that psilocybin effectively treats common comorbidities such as anxiety and treatment-resistant depression, though the review focuses mainly on MDMA for PTSD.
Sex-specific outcomes of developmental stress and psilocybin intervention on the brain and behavior 2026 preclinical animal study Mixed Psilocybin broadly reversed effects of developmental stress, with different behavioral domains affected in males and females.
Policy Considerations for Psychedelics in Research and Medicine – What’s Next on the Schedule? 2026 review Supports Notes FDA Breakthrough Therapy designations including psilocybin for treatment-resistant depression and LSD for generalized anxiety disorder, while most psychedelics remain Schedule I.
Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms 2026 observational survey 2841 Mixed Past-year psilocybin and alcohol co-use was associated with fewer depressive symptoms, and psilocybin use was related to lower anxiety symptoms only after removing other substance covariates.
Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 preclinical experimental Opposes Chronic psilocin microdosing did not affect most behaviors or neurogenesis and showed a small anxiogenic effect.
Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes 2026 RCT reanalysis Supports Women receiving psilocybin showed greater anxiety reductions than men, while sex differences on other outcomes were small and uncertain.
Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression. 2026 open-label trial 15 Supports A single 25 mg dose with psychological support produced sustained anxiety improvements through 12 months, with a 59% reduction at week 3, though effects were no longer significant after accounting for depression improvement.

Points of agreement

  • Multiple controlled and open-label trials in cancer and depression populations report substantial anxiety reductions after psilocybin with psychological support.
  • Benefits often persist for months (roughly 6-12 months) after only one to three sessions.
  • Systematic reviews describe the evidence as promising but early, with small samples and frequent open-label designs.
  • Acute anxiety or panic can occur, mainly at higher doses, and is usually manageable with support.
  • Anxiety improvements frequently co-occur with and track improvements in depressive symptoms.

Conflicts

  • Some studies report anxiety reduction as a primary benefit, while others find anxiety gains are no longer significant once depression improvement is accounted for.
  • Psilocybin is reported both to reduce anxiety and, at high doses or in uncontrolled settings, to provoke acute anxiety and panic.
  • A small anxiogenic effect in chronic microdosing in rats contrasts with anxiolytic effects reported at therapeutic doses in humans.
  • Sex-specific findings suggest women may benefit more on anxiety, but other outcomes show small or uncertain sex differences.

Gaps

  • Most clinical samples are small (12-51 participants) and few trials are fully blinded or use anxiety as the primary endpoint.
  • Durability beyond 12 months is largely unstudied.
  • Dose-response for anxiety is unclear, and low-dose or microdosing evidence is minimal.
  • Populations studied are narrow (mainly cancer and depression); generalized anxiety disorder, older adults, and diverse groups are understudied.
  • Whether anxiety benefits are independent of antidepressant effects remains unresolved.
  • Mechanistic work is mostly animal or in vitro and not yet translated to clinical anxiety.
Browse these studies in the library

Common questions

What does the research agree on about psilocybin for anxiety?
  • Multiple controlled and open-label trials in cancer and depression populations report substantial anxiety reductions after psilocybin with psychological support.
  • Benefits often persist for months (roughly 6-12 months) after only one to three sessions.
  • Systematic reviews describe the evidence as promising but early, with small samples and frequent open-label designs.
  • Acute anxiety or panic can occur, mainly at higher doses, and is usually manageable with support.
  • Anxiety improvements frequently co-occur with and track improvements in depressive symptoms.
Where do studies on psilocybin for anxiety conflict?
  • Some studies report anxiety reduction as a primary benefit, while others find anxiety gains are no longer significant once depression improvement is accounted for.
  • Psilocybin is reported both to reduce anxiety and, at high doses or in uncontrolled settings, to provoke acute anxiety and panic.
  • A small anxiogenic effect in chronic microdosing in rats contrasts with anxiolytic effects reported at therapeutic doses in humans.
  • Sex-specific findings suggest women may benefit more on anxiety, but other outcomes show small or uncertain sex differences.
What is still unknown about psilocybin for anxiety?
  • Most clinical samples are small (12-51 participants) and few trials are fully blinded or use anxiety as the primary endpoint.
  • Durability beyond 12 months is largely unstudied.
  • Dose-response for anxiety is unclear, and low-dose or microdosing evidence is minimal.
  • Populations studied are narrow (mainly cancer and depression); generalized anxiety disorder, older adults, and diverse groups are understudied.
  • Whether anxiety benefits are independent of antidepressant effects remains unresolved.
  • Mechanistic work is mostly animal or in vitro and not yet translated to clinical anxiety.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Psilocybin for anxiety, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Psilocybin for anxiety or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

308 articles · 86 from the last two years · 306,326 participants across 110 studies reporting sample size

Common study designs

review 91 systematic review 32 cross-sectional survey 13 randomized controlled trial 12 theoretical or philosophical paper 9

Research volume by year

Compare topics →

306 studies whose primary subject is psilocybin for anxiety since 2006

Studies about psilocybin for anxiety per year, 2006 to 2026, peaking at 51 in 2023 Bar chart: one bar per year, taller where more studies were published that year. 0 30 60 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about psilocybin for anxiety per year, 2006 to 2026, peaking at 51 in 2023
Year Studies
2006 2
2007 0
2008 0
2009 0
2010 2
2011 0
2012 0
2013 1
2014 3
2015 1
2016 8
2017 6
2018 12
2019 10
2020 18
2021 35
2022 45
2023 51
2024 32
2025 44
2026 36

Research

Synthesize the evidence →

Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis.

Psychopharmacology October 26, 2026 Aline Frick, Grace Blest‐hopley, Manesh Girn et al.

Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, females remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex differences across multiple...

DOI: 10.1007/s00213-026-07177-7 (opens in new tab) Full text (opens in new tab) Anxiety Major depressive disorder Psilocybin Anhedonia +3

Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice.

Psychopharmacology October 17, 2026 Sixtine Fleury, Yian Shang, Katherine M. Nautiyal

Psilocybin can produce rapid and sustained antidepressant-like and anxiolytic effects, yet the receptor and circuit mechanisms underlying these behavioral changes remain unclear. While the serotonin 2A receptor mediates psilocybin's acute psychedelic effects, psilocin (the active metabolite of psilocybin) binds many serotonin receptor subtypes. Our prior work has identified the serotonin 1B...

DOI: 10.1007/s00213-026-07184-8 (opens in new tab) Full text (opens in new tab) Anxiety Psilocybin 5-ht1br Desynchrony +2

Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe Anxiety

Drugs and Drug Candidates August 12, 2026 M. Salgaço, D. D. Farias, Mariela Zucolo de Souza et al.

Background/Objectives: This study investigated the effects of a single dose of psilocybin-containing Psilocybe cubensis extract on gut microbiota composition, microbial metabolism, and intestinal immune-related responses. Methods: A single dose of P. cubensis extract (35 mg/L) was subjected to colonic fermentation using the SHIME® model inoculated with fecal microbiota from individuals with...

DOI: 10.3390/ddc5030046 (opens in new tab) Full text (opens in new tab)

A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults.

medRxiv July 19, 2026 Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al. preprint

Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10-25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be separated from its hallucinogenic activity remains unresolved. To address this gap, we conducted a Phase...

DOI: 10.64898/2026.07.16.26358273 (opens in new tab) Psilocybin Anxiety Mescaline Lysergic acid diethylamide +11

Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder

Journal of Education, Health and Sport July 16, 2026 Jakub Bajer, Aleksandra Włodarczyk, Hubert Kulawinek et al.

Background. Post-Traumatic Stress Disorder (PTSD) is an important public health challenge typically treated with trauma-focused psychotherapy and Selective Serotonin Reuptake Inhibitors (SSRIs). However, high rates of residual symptoms associated with these standard treatments have led to a renewed interest in psychedelic-assisted therapies. Aim. This review attempts to examine emerging...

DOI: 10.12775/jehs.2026.94.73071 (opens in new tab) Traumatic stress Ketamine Psilocybin Anxiety disorder +5

Sex-specific outcomes of developmental stress and psilocybin intervention on the brain and behavior

Universitätsbibliothek der LMU July 9, 2026 Sowmya Narayan

Stress exposure during periods of neurodevelopment is an established risk factor for the onset of stress-related mental illnesses in adulthood, which have differences in presentation and treatment response depending on an individual’s sex, and are difficult to treat due to a lack of complete biological understanding. A more holistic biological perspective of the adult brain after stress...

DOI: 10.5282/edoc.35588 (opens in new tab) Psilocybin Anxiety Intervention counseling Perspective graphical +9

Policy Considerations for Psychedelics in Research and Medicine – What’s Next on the Schedule?

Journal of Science Policy & Governance July 2, 2026 Matthew A. Boehm, Oriana Mayorga

There is growing interest in psychedelic compounds such as psilocybin, 3,4-metheylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) given emerging research on potential uses as treatments for a variety of health conditions. The United States Food and Drug Administration (FDA) has granted multiple “Breakthrough Therapy” designations to various...

DOI: 10.38126/jspg280103 (opens in new tab) Psilocybin Anxiety Lysergic acid diethylamide Variety cybernetics +6

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms

Journal of Drug Issues July 1, 2026 Haley M Hummel, Alexia N Obrochta, David C. R. Kerr et al.

Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-year psilocybin and alcohol co-use...

DOI: 10.1177/00220426261466154 (opens in new tab) Psilocybin Anxiety Cannabis Hallucinogen +8

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, Biochemistry, and Behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

DOI: 10.1016/j.pbb.2026.174231 (opens in new tab) Full text (opens in new tab) Anxiety Depression Behavioral testing Hippocampal neurogenesis +3

Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes

Research Square June 19, 2026 Aline Frick, Grace Blest‐hopley, Manesh Grin et al. preprint

Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex...

DOI: 10.21203/rs.3.rs-9880403/v1 (opens in new tab) Psilocybin Major depressive disorder Anxiety disorder Serotonergic +10

Clinical trials

All psilocybin for anxiety trials →